Therapeutic approach to familial Mediterranean fever: A review update

Clinical and Experimental Rheumatology

Volumn 29, Issue 4 SUPPL. 67, 2011, Pages

  Ozturk, M A ^a,f   Kanbay, M ^b   Kasapoglu, B ^c   Onat, A M ^a   Guz, G ^a   Furst, D E ^d   Ben Chetrit, E ^e  

^a GAZI UNIVERSITY   (Turkey)

^b Kayseri Training and Research Hospital   (Turkey)

^c FATIH UNIVERSITY   (Turkey)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Colchicine; Familial Mediterranean fever; Treatment

Indexed keywords

ALPHA INTERFERON; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DILTIAZEM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERYTHROMYCIN; ESTROGEN; GESTODENE; INDINAVIR; INFLIXIMAB; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MEVINOLIN; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINIDINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERUM AMYLOID A; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; VERAPAMIL; ACUTE PHASE PROTEIN; ANAKINRA; AZATHIOPRINE; EPRODISATE; ETANERCEPT; GOLD; METHOTREXATE; METHYLPREDNISOLONE; PAROXETINE; PLACEBO; PREDNISOLONE; PYRIN; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL DISEASE; ABDOMINAL PAIN; ALOPECIA; ANAPHYLACTOID PURPURA; ARTHRITIS; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CHILL; COCHRANE LIBRARY; COMA; DEATH; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE INCREASE; DRUG FATALITY; DRUG OVERDOSE; EMBASE; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEVER; GENE MUTATION; GRAPEFRUIT JUICE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER INJURY; MALE FERTILITY; MEDLINE; MENSTRUATION; NAUSEA; NEUROMUSCULAR DISEASE; PARALYSIS; PERISTALSIS; PERITONITIS; PLEURISY; POLYARTERITIS NODOSA; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; RESPIRATORY FAILURE; REVIEW; SEIZURE; SHOCK; SIDE EFFECT; ST SEGMENT ELEVATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ACUTE PHASE RESPONSE; AMYLOIDOSIS; ARTHRALGIA; ATHEROSCLEROSIS; AZOOSPERMIA; BREAST FEEDING; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG MILK LEVEL; ECG ABNORMALITY; GASTROINTESTINAL SYMPTOM; GOUT; HYPERPERISTALSIS; INFECTION; INJECTION SITE REACTION; KIDNEY AMYLOIDOSIS; KNEE ARTHRITIS; LOW DRUG DOSE; MEFV GENE; MYALGIA; NONHUMAN; OLIGOSPERMIA; PREGNANCY OUTCOME; PROTRACTED FEBRILE MYALGIA; REMISSION; SPERMATOZOON MOTILITY; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ANTIRHEUMATIC AGENTS; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY; PREGNANCY COMPLICATIONS; TUBULIN MODULATORS;

EID: 80855165285     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. BEN-CHETRIT E, LEVY M: Familial Mediterranean fever. Lancet 1998; 351: 659-64. (Pubitemid 28098460)
2. GRATEAU G: Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford) 2004; 43: 410-5. (Pubitemid 38489355)
3. BEN-CHETRIT E, TOUITOU I: Familial Mediterranean fever in the world. Arthritis Rheum 2009; 63: 1447-53.
4. GOLDFINGER SE: Colchicine for familial Mediterranean fever. N Eng J Med 1972; 287: 1302.
5. OZKAN E, OKUR O, EKMEKCIA et al: A new approach to the treatment of periodic fever. Med Bull Istanbul Med Fac 1972; 5: 44-9.
6. COPEMAN WSC: A Short History of the Gout and the Rheumatic Diseases. Los Angeles, CA: University of California Press; 1964.
7. EL-SHANTI HI: Familial mediterranean fever and renal disease. Saudi J Kidney Dis Transpi 2003; 14:378-5.
8. ZEMER D, REVACH M, PRAS MA et al.: A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N EngU Med 1974; 291: 932-4.
9. DINARELLO CA, WOLFF SM, GOLDFINGER SE et al.: Colchicine therapy for familial Mediterranean fever: a double-blind trial. N EngU Med 1974; 291: 934-7.
10. Şimşek B, ISLEK I, Şimşek T, Küçüködük S, CENGIZ K: Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant 2000;15:281-2. (Pubitemid 30064291)
11. KIM S, IKUSAKA M, MIKASA G et al.: Clinical study of 7 cases of familial Mediterranean fever with MEFV gene mutation. Intern Med 2007;46:221-5. (Pubitemid 46403663)
12. TSUCHIYA-SUZUKI A, YAZAKI M, NAKAMURA A et al.: Clinical and genetic features of familial Mediterranean fever in Japan. J Rheumatol 2009; 36: 1671-6.
13. KALLINICH T, HAFFNER D, NIEHUES T et al.: Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119:e474-e483. (Pubitemid 46397797)
14. BEN-CHETRIT E, LEVY N: Colchicine: 1998 Update Semin Arthritis Rheum 28: 48-59.
15. KUNCL RW, DUNCAN G, WATSON D et al.: Colchicine myopathy and neuropathy. N EngU Med 1987; 316: 1562-8. (Pubitemid 17083593)
16. OZEN S, BILGINER Y, AKTAY AYAZ N, CALGUNERI M: Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011 Mar; 38: 516-8.
17. BEN-CHETRIT E, AAMAR S: About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009; 27 (Suppl. 53): S1-S3.
18. BEN-CHETRIT E.OZDOGANH: Non-response to colchicine in FMF-definition, causes and suggested solutions. Clin Exp Rheumatol 2008; 26 (4 Suppl. 50): S49-S51.
19. ERKEN E, OZER HT, BOZKURT B et al.: Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine 2008; 75: 370-2.
20. TUNCA M, AKAR S, SOYTÜRk M et al.: The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22 (4 Suppl. 34): S37-S40.
21. TWEEZER-ZAKS N, RABINOVICH E, LIDAR M et al.: Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. J Rheumatol 2008; 35: 1362-5. (Pubitemid 352000785)
22. CALGUNERI M, APRAS S, OZBALKAN Z et al.: The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22 (4 Suppl. 34):S41-S44.
23. SEYAHI E, OZDOGAN H, CELIK S et al..: Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006; 24 (Suppl. 42): S99-S103. (Pubitemid 44696888)
24. MOR A, PILLINGER MH, KISHIMOTO M et al.: Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007; 13: 38-40. (Pubitemid 46213843)
25. SAKALLIOGLU O, DUZOVA A, OZEN S: Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006; 24: 435-7. (Pubitemid 44363547)
26. METYAS S, ARKFELD DG, FORRESTER DM et al.: Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004; 10: 134-7. (Pubitemid 38821988)
27. NAKAMURA A, MATSUDA M, TAZAWA K et al.: Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med 2007; 46: 1247-9. (Pubitemid 47354446)
28. CAPORALI R, PALLAVICINI FB, FILIPPINI M et al.:Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009; 8: 274-80.
29. CHAE JJ, WOOD G, MASTERS SL et al.: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1B production. Proc Natl Acad Sci USA 2006; 103: 9982-7. (Pubitemid 43993609)
30. ROLDAN R, RUIZ AM, MIRANDA MD et al.: Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008; 75: 504-5.
31. GATTRINGER R, LAGLER H, GATTRINGER KB et al.: Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007; 37: 912-4. (Pubitemid 350029205)
32. KUIJK LM, GOVERS AM, FRENKEL J et al.: Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007; 66: 1545-6. (Pubitemid 350032672)
33. CALLIGARIS L, MARCHETTI F, TOMMASINI A et al.: The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008; 167: 695-6. (Pubitemid 351503491)
34. BELKHIR R, MOULONGUET-DOLERIS L, HACHULLA E et al.: Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007; 146:825-6. (Pubitemid 351650515)
35. OZEN S, BILG1NER Y, AYAZ NA, CALGUNERI M: Anti-Interleukin 1 treatment for patients with Familial Mediterranean Fever Resistant to Colchicine. J Rheumatol 2011; 38: 516-8.
36. ONAT AM, OZCAKAR L, OZTURK MA et al.: Plasma and platelet serotonin levels in familial Mediterranean fever. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S16-S20
37. OZCAKAR L, ONAT AM, KAYMAK SU et al.: Selective serotonin reuptake inhibitors in familial Mediterranean fever: Are we treating depression or inflammation? Rheumatol Int 2005;25:319-0. (Pubitemid 40767843)
38. ONAT AM, OZTORK MA, OZCAKAR L et al.: Selective serotonin reuptake inhibitors reduce the attack frequency in familial Mediterranean Fever. Tohoku J Exp Med 2007; 211:9-14. (Pubitemid 46062215)
39. PERU H, ALTUN B, DOGAN M et al.: The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 2008; 27: 689-94. (Pubitemid 351650029)
40. SARI I, KARAOGLU O, CAN G et al.: Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 2007; 26: 1467-73. (Pubitemid 47193563)
41. YALCINKAYA F, CAKAR N, ACAR B et al.: The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. Rheumatol Int 2007; 27: 517-22. (Pubitemid 46411898)
42. DUZOVA A, BAKKALOGLU A, BESBAS N et al.: Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003; 21: 509-14. (Pubitemid 36950324)
43. INFEVERS The registry of Familial Mediterranean Fever (FMF) and hereditary Autoinflammatory Disorders Mutations, http:// fmf.igh.cnrs.fr/ISSAID/ infevers/. Accessed 11 Mar 2008
44. TOUITOU I: Standardized testing for mutations in familial Mediterranean fever. Clin Chem 2003; 49: 1781-2. (Pubitemid 37340311)
45. LIVNEH A, LANGEVITZ P, SHINAR Y et al.: MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 1999; 6: 1-6. (Pubitemid 29249929)
46. TOUITOU I, SARKISIAN T, MEDLEJ-HASHIM M et al.\ INTERNATIONAL STUDY GROUP FOR PHENOTYPE-GENOTYPE CORRELATION IN FAMILIAL MEDITERRANEAN FEVER: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56: 1706-12. (Pubitemid 46764102)
47. INCE E, CAKAR N, TEKIN M et al.: Arthritis in children with familial Mediterranean fever. Rheumatol Int 2002; 21:213-7. (Pubitemid 34328054)
48. TUNCA M, AKAR S, ONEN F et al.; TURKISH FMF STUDY GROUP: Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84: 1-11. (Pubitemid 40130180)
49. OZCAKAR L, ONAT AM, URETEN K et al.: Sonographic evaluation of the tendons in familial Mediterranean fever and Behçet's disease. Joint Bone Spine 2006; 73: 514-7. (Pubitemid 44848038)
50. BAKKALOGLU SA, AKSU T, GOKER B et al.: Sulphasalazine treatment in protracted familial Mediterranean fever arthritis. Eur J Pediatr 2009; 168: 1017-9.
51. DEMIRAG MD, OZTURK MA, GOKER B et al.: Intramuscular gold for the treatment of seronegative spondyloarthropathy associated with familial Mediterranean fever. Rheumatol Int 2008; 29: 77-9.
52. URETEN K, CALGUNERI M, ONAT AM et al.: Interferon alfa in protracted arthritis of familial Mediterranean fever: a robust alternative for synovectomy. Ann Rheum Dis 2004; 63: 1527. (Pubitemid 39433970)
53. DAYSAL S., AKCILG, GOKER B et al.: Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 2005; 53: 146-7. (Pubitemid 40216369)
54. TEKIN M, YALCINKAYA F, Tümer N et al.: Familial Mediterranean fever - renal involvement by diseases other than amyloid. Nephrol Dial Transplant 1999; 14:475-9. (Pubitemid 29062821)
55. OZEN S, BEN-CHETRIT E, BAKKALOGLU A et al.: Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum 2001; 30: 281-7. (Pubitemid 32172733)
56. CALGUNERI M, APRAS S, OZBALKAN Z, OZTURK MA: The efficacy of interferon-alpha in a patient with resistant familial Mediterranean fever complicated by polyarteritis nodosa. Intern Med 2004; 43: 612-4. (Pubitemid 39206705)
57. LANGEVITZ P, ZEMER D, LIVNEH A, SHEMER J, PRAS M: Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 1994; 21: 1708-9. (Pubitemid 24285488)
58. KAPLAN E, MUKAMEL M, BARASH J et al.: Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol 2007; 25 (Suppl. 45): SI 14-7.
59. TUFAN G, DEMIR S: Uncommon clinical pattern of FMF: protracted febrile myalgia syndrome. Rheumatol Int 2010; 30: 1089-90.
60. SAYARLIOGLU H, ERKOC R, SAYARLIOGLU M et al.: Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006; 27: 197-9. (Pubitemid 46088281)
61. YUKSEL S, YALCINKAYA F, ACAR B et al.: Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2006; 45: 1307-8. (Pubitemid 44542076)
62. DEMBER LM, HAWKINS PN, HAZENBERG BP et al.; EPRODISATE FOR AA AMYLOIDOSIS TRIAL GROUP: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-60. (Pubitemid 46883769)
63. BILGINER Y, AYAZ NA, OZEN S: Anti-1L-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010; 29: 209-10.
64. BAKER ME: Colchicine inhibits mitogenesis in CI300 neuroblastoma cells that have been arrested in GO. Nature 1976; 262: 785-6.
65. MERLIN HE: Azoospermia caused by colchicine - a case report. Fertil Steril 1972: 23, 180-1.
66. BARSOU IS: The effect of colchicine on the spermatogenesis of rabbits. J Pharmacol Exp Ther 1955; 113:319-22.
67. LEVY M, YAFFE C: Testicular function in patients with familial Mediterranean fever, on long-term colchicine treatment. Fertil Steril 1978; 29: 667-8.
68. BREMNER WJ, PANLSON CA: Colchicine and testicular function in man. N Engl J Med 1976; 294: 1384-5.
69. SARICA K, SUZER O, GURLER A, BALTACI S, OZDILER E, D1NCELC: Urological evaluation of Behçet patients and the effect of colchicine on fertility. EurJMol 1995; 22: 39-42.
70. HAIMOV-KOCHMAN R, PRUS D, BENCHETRIT E: Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod 2001; 16: 1218-20. (Pubitemid 32544694)
71. BEN-CHETRIT A, BEN-CHETRIT E, NITZAN R, RON M: Colchicine inhibits spermatozoal motility in vitro. Int J Fertil Menopausal Stud 1993; 38: 301-4. (Pubitemid 23324840)
72. BEN-CHETRIT E, BERKUN Y, BEN-CHETRIT E, BEN-CHETRIT A: The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum 2004; 34: 549-52. (Pubitemid 40288132)
73. SCHWARTZ J: Periodic peritonitis, onset simultaneously with menstruation. Ann Intern Med 1960; 53: 407-11.
74. GOLDEN RL, WEIGERS EW, MEAGHER JG: Periodic fever and menses. Am J Obstet Gynecol 1973; 855-6.
75. MILANO AM: Familial Mediterranean fever associated with menstruation. Am J Gastroenterol 1981; 76: 363-4.
76. BEN-CHETRIT E, BEN-CHETRIT A: Familial Mediterranean fever and menstruation. BJOG 2001,108:403-7. (Pubitemid 32269867)
77. KOH KK, BUI MN, MINCEMOYER R, CANNON RO 3RD: Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997; 80: 1505-7. (Pubitemid 27523042)
78. CHAUDOREILLE MM, PEYROT V, BRAGUER D, CODACCIONI F, CREVAT A: Qualitative study of the interaction mechanism of estrogenic drugs with tubulin. Bichem Pharmacol 1991;41:685-93. 80, 51.
79. BEN-CHETRIT E, LEVY M: Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991;20:241-6.
80. RABINOVITCH O, ZEMER D, KUKIA E et al. Colchicine treatment in conception and pregnancy: two hundred and thirty one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 22: 145-6.
81. BARKAI G, MEITAL Y, CHETRIT A, BARELL V, AVIRAM A, ZEMER D: Evaluation of pregnancy outcome among FMF colchicine treated women. 1st International Conference on FME September 1997, Jerusalem, Israel (abstract).
82. BEN-CHETRIT E, BEN-CHETRIT A, BERKUN Y, BEN-CHETRIT E: Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res 2010; 62: 143-8.
83. BRIGGS GG, FREEMAN RK, YAFFE RS: Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins, 1994.
84. MILUNSKYJ M., MILUNSKY A: Breastfeeding during colchicine therapy for familial Mediterranean fever. J Pediatr 1991; 119: 163.
85. BEN-CHETRIT E, SCHERRMANN J-M, LEVY M: Colchicine in breast-milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39: 1213-7. (Pubitemid 26240237)
86. SCHONHASTING M, MENDE G, SIEBERT G: The metabolism of colchicine by mammalian liver microsomes. J Physiol Chem Biol 1974; 355: 1391-9.
87. LEIGHTON SA, BAY MK, MALDONADO AL, JOHNSON RF, SCHENKER S, SPEEG KV: The effect of liver dysfunction on colchicine pharmacokinetics in the rat. Hepatology 1990; 11:21-5.
88. BEN-CHETRIT E, SCHERRMANN J-M, ZILBER- KATZ E, LEVY M: Colchicine disposition in FMF patients with renal diseases. J Rheumatol 1994; 21: 710-3.
89. LEIGHTON JA, BAY MK, MALDONADO AL, SCHENKER S, SPEEG KV: Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology 1991; 14: 1013-5.